VEGFA and renal cell adenocarcinoma: Development and progression of advanced RCC have been slowed or even arrested through immune checkpoint inhibitor (ICI) combination therapy (ipilimumab plus nivolumab), which, in patients with intermediate or poor risk, showed a better overall survival (OS) than VEGF target therapy recently [6].